Vonderheid 1987.
Study characteristics | ||
Methods | This was a randomised, double‐blind, within‐participant trial, which lasted 4 weeks. | |
Participants | The study recruited 6 participants (2 lesions per treatment) with plaque phase MF, MFCG stage nomenclature of 1979 stage IA (T1, Nx, T0, M0), stage IB (T2, Nx, T0, M0), or stage IIA (T2, N1, T0, M0) Demographics of the included participants
Exclusion criteria of the trial
|
|
Interventions |
|
|
Outcomes |
Outcomes of the trial
|
|
Notes | The funding body and conflicts of interest were not declared. This study was conducted in a tertiary care centre in the USA. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Lesions were allocated by a random code; no further information was given; information was sought, but we received no response. |
Allocation concealment (selection bias) | Unclear risk | Information was sought, but we received no response. |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | The trial was described as double‐blind for the first part, which we data extracted. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | No separate outcome assessor was described. |
Incomplete outcome data (attrition bias) All outcomes | Low risk | ITT analysis was carried out. There were no dropouts. |
Selective reporting (reporting bias) | Unclear risk | This was unknown. We contacted the corresponding author for additional outcome data, but we received no reply within 4 weeks. |
Other bias | Unclear risk | There were insufficient information to permit judgement. |